BTIG cuts Tvardi Therapeutics stock price target to $15 due to IPF trial setback

Photo of author

By [email protected]




BTIG cuts Tvardi Therapeutics stock price target to $15 due to IPF trial setback



[og_img]

Source link

Leave a Comment